QuidelOrtho (NASDAQ: QDEL) shares surged 9.79% in after-hours trading on Tuesday, following the release of the company's second-quarter 2025 financial results that significantly exceeded analyst expectations. The diagnostic healthcare product manufacturer demonstrated strong performance despite challenging market conditions.

The company reported an adjusted earnings per share (EPS) of $0.12, dramatically outperforming the analyst consensus estimate of $0.01. This represents a remarkable 1400% beat and a 271.43% increase from the same period last year when the company posted a loss of $0.07 per share. QuidelOrtho's revenue for the quarter came in at $613.9 million, surpassing the analyst estimate of $609.978 million by 0.64%. However, it's worth noting that this figure represents a 3.63% decrease from the $637 million reported in the same quarter of the previous year.

Despite the slight year-over-year revenue decline, investors appear to be focusing on QuidelOrtho's ability to exceed expectations and improve profitability. The company also reiterated its full-year 2025 financial guidance, suggesting confidence in its future performance. The strong after-hours stock movement indicates that market participants are reacting positively to QuidelOrtho's earnings beat and outlook, potentially seeing it as a sign of the company's resilience and growth potential in the competitive diagnostic healthcare sector.